Matthew Adrian Spear MD

Radiation Oncology•Rancho Santa Fe, CA

Physician

Join to View Full Profile

PO box 1108Rancho Santa Fe, CA 92067
Phone+1 858-352-8557

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 1994 - 1997
University of HawaiiInternship, Transitional Year, 1993 - 1994
Stanford University School of MedicineClass of 1993

Certifications & Licensure

CA State Medical License 1998 - 2025
NC State Medical License 2011 - 2012

Clinical Trials

Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2006 Apr 01
Completed
Phase 1
Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2008 Feb 01
Completed
Phase 1, Phase 2
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Start of enrollment: 2016 Sep 22
Completed
Phase 1, Phase 2
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies Start of enrollment: 2014 Sep 10
Terminated
Phase 1, Phase 2
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) Start of enrollment: 2017 Sep 20
Terminated
Phase 1, Phase 2
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 Start of enrollment: 2018 Oct 29
ACTIVE_NOT_RECRUITING
PHASE1
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) Start of enrollment: 2020 Feb 28
TERMINATED
PHASE1
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus Start of enrollment: 2025 Jan 15
NOT_YET_RECRUITING
PHASE1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

112 citations
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung can...
Michael Millward, Timothy J. Price, Amanda R. Townsend, Christopher Sweeney, Andrew Spencer
Investigational New Drugs. 2012-12-01
56 citations
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.
Michael Millward, P. N. Mainwaring, Alain C. Mita, Kristine C. Federico, G. K. Lloyd
Investigational New Drugs. 2012-06-01
27 citations
Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic
Matthew A. Spear, Patricia LoRusso, Alain C. Mita, Monica M. Mita
Current Drug Targets. 2011-11-30

Abstracts/Posters

Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)Clinically Relevant Abstract
Matthew A. Spear, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019